chang fair valu estim
page full analyst note oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
aim transform human health practic
leadership genom sequenc firm provid broad rang
instrument relat consum help research
clinician identifi understand genet variat scale
project wide popul genom initi
pursu mani countri narrow non-invasive
prenat screen believ continu benefit
rapidli expand applic genom sequenc
tool innov select acquisit
past decad technolog advanc
sequenc industri larg led brought
cost assembl one genom nearli billion
human genom project complet
introduc highseq earli
innov like recent launch novaseq continu push
cost expect novaseq eventu
enabl genom could greatli increas
access genom sequenc lower cost genom
sequenc could wide appeal clinic diagnost
applic especi oncolog reproduct health
technolog perspect beat current
competit nearli everi measur -- run cost
turnaround time read length throughput error rate --
expect domin continu mani year threat
exampl think new sequenc techniqu includ nanopor
sequenc hold promis howev given difficulti
commerci new sequenc tool especi compar
test larg instal system base remain
unconvinc emerg system dethron
near futur meantim continu pursu
intern innov exist new sequenc method
also believ remain astut buyer compet
technolog help remain relev even
in-hous effort eventu eclips
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
provid tool servic analyz genet materi life
scienc clinic lab applic compani gener revenu
sequenc tool dedic consum sale
human larg organ lower throughput tool enabl
applic requir smaller data output viral cancer
tumor screen also sell microarray sale enabl
lower-cost focus genet screen primarili consum
agricultur applic servic account sale includ
basic mainten servic clinic lab applic non-invasive
prenat oncolog rare-diseas screen whole genom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
lag chang fair valu estim oct
narrow-moat turn stronger-than-expect
third-quart revenu adjust earn per share
led rais ep outlook expect
howev free cash flow still track
view consid fair valu estim
base discount cash flow remain cautiou
strong perform incom statement
without similar improv cash flow statement
therefor chang fair valu estim even
make moder adjust estim
quarter revenu grew year year
growth
manag previous predict access fee paid
qiagen
compani diagnost
collabor appear buoy result
somewhat also sequenc busi remain strong
growth quarter consumer-driven
array busi remain declin year
throughput nextseq
medium throughput
deliv second-highest quarter system sale sinc
respect launch high throughput strength
due part unit kingdom popul sequenc
initi medium throughput strength relat
on-going expans diagnost applic
novaseq
top-lin trend signific cost control
includ year-over-year cut major expens line like
research develop sell gener
administr abl boost adjust ep
quarter significantli higher
consensu result rais ep
outlook howev illumina
express caution futur result relat
on-going weak consum end market
highlight similar dynam china
incom statement strength
translat strong cash flow growth year
quarter nine month end septemb free
cash flow declin rel prior-year period
compani gener million year date
compar million period last
year base perform far reduc
previou project roughli million free cash
flow new view cash flow contribut
maintain fair valu estim despit higher-
than-expect incom statement result third quarter
trim fair valu estim
per share lower expect
growth particularli margin expans
throughout five-year forecast period new fair valu
estim valu time expect earn
time expect earn
expect grow revenu
compound annual thank healthi demand
sequenc technolog project assum on-going
strength research applic well grow
adopt sequenc
custom still anticip research budget
continu priorit genom sequenc spend due
research advanc technolog provid
clinic diagnost market remain larg opportun
sinc sequenc potenti disrupt
segment older diagnost test addit creat
prenat screen repres near-term clinic growth
opportun ultim pace growth market
remain somewhat uncertain
constraint regulatori issu reimburs hurdl
among clinic custom base meanwhil expect
continu headwind smaller microarray
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
earn per share grow
compound annual next five year
fair valu approxim time
expect earn time expect earn
model slower penetr genom sequenc
technolog competit
emerg
platform particularli lower-throughput market
scenario revenu grow compound annual
next five year oper margin declin
slightli earn per share grow
period prop share repurchas
believ oper strong narrow moat
around genet analysi tool servic estim
oper share
sequenc market domin
high-throughput segment technolog help
scientist gener world sequenc data
purchas solexa genom reader instrument
earli sinc continu innov
significantli reduc cost sequenc therebi
enabl rapid expans sequenc applic
disrupt technolog remain high-risk concern
industri think firm
differenti technolog on-going innov larg
instal system base creat signific entri barrier
competitor therefor expect gener
econom profit current time capit
cost least next decad
sourc competit advantag appear
root intang asset switch cost
reli intang asset
issu pend patent unit state
earli keep competit bay applic
patent typic enjoy term keep
segment
cannib result declin sequenc price
expect earn per share grow
compound annual assum earn grow
faster sale oper margin rise
compani repurchas share use
weight averag cost capit discount
give high uncertainti rate due
compani product concentr early-stag genom
sequenc market combin potenti
disrupt entrant highli technic field
bull-cas scenario valu per
share time expect earn time
expect earn scenario assum
revenu grow compound annual next
five year faster market adopt genom sequenc
less pressur compet technolog less
competit pressur think oper margin rise
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
competitor directli copi technolog long
period time sinc even slightli differenti technic
featur caus end user prefer one tool
similar tool compani precis scientif end market
technolog
contribut competit advantag addit even
similar tool difficult firm engin
given complex field leav
domin player high-throughput applic
limit competit lower-throughput field
thermo fisher scientif
think barrier entri high genom sequenc
thank intersect three highli technic
instrument
complex data analysi expect ventur capit
continu flow early-stag market product
commerci prove extrem difficult
alway emerg small-scal method develop
major research univers manufactur scalabl
develop molecular enzym need process
amplifi genet materi microfluid engin
complex softwar algorithm assembl massiv
amount data support custom servic creat
sizabl hurdl sector focu early-stag
technolog ventur capit arm gener
acquisit prowess help give access new
technolog includ pend acquisit pacif
bioscienc sell long-read technolog could
use applic like de novo genom sequenc
develop averag past five year
fund advanc boost featur throughput flow
cell densiti read length cycl time faster camera
chemistri process expect instrument
continu lead industri sequenc cost
throughput accuraci forese futur
exampl human genom project took year
billion complet technolog
help reduc cost whole genom sequenc faster
moor law semiconductor
pace cost reduct innov unparallel
field creat signific entri barrier
potenti rival opinion firm rest
laurel either manag highlight
work path enabl genom
forese futur could expand
advantag applic genet test even
also benefit switch cost end user
wish use sequenc system dedic
reagent flow cell requir
compani sale dedic larg
instal base sequenc abl
count signific revenu stream relat
instrument like extend five year
long sequenc tool remain relev
abl count substanti consum revenu
use life instrument
life
gener differenti properti tool
affect cost accuraci speed variou test
enabl product featur creat intang asset
inform decis use tool specif
applic thank strong emphasi intern
innov includ spend sale research
relev sequenc technolog also
appear like continu rel long period
citat industri public workflow
develop around system need repeat
consist therefor think end user would need
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
signific reason jump ship tool
reproduc end user train perspect
switch cost pervas life scienc lab
may even becom import clinic lab
regul play role ensur test accuraci
workflow need standard less skill
threat product keep moat rate
narrow rather wide exampl nanopor technolog
spearhead oxford nanopor
technolog seen invest like
roch strato genia continu repres threat
current sequenc standard nanopor
technolog could lower sequenc cost associ
sampl prepar amplif reagent also
enabl long read length fast run time much simpler
sequenc assembl data analysi far ont
devic minor competit threat
lower throughput product detect
accuraci appear issu ont technolog
lead rel high error rate also base
cursori analysi ont technolog think compani
repres greater threat long-read
technolog time could threaten core
busi eventu beyond nanopor technolog
sequenc techniqu could emerg eclips
technolog eventu well think
advantag like lead econom profit
least next year remain uncertain
advantag extend next year given
on-going disrupt technolog risk field
on-going threat disrupt technolog keep
moat rate narrow instead wide award
posit moat trend result strengthen
intang asset increas switch cost
continu innov recent introduct
low- mid- high-throughput applic
new product add firm intang asset
relat patent protect intellectu properti
differenti technolog unfortun transpar
perspect histori announc new
technolog readi market make
howev given consist spend close
sale expect continu improv
exist technolog stave competit enter new
applic introduc new sequenc approach
futur histori indic new launch
like focu reduc unit cost genom
sequenc expand possibl applic
technolog healthcar along compani
opportun also compani continu make select
acquisit expand differenti technolog
pend acquisit pacif bioscienc
instal system base
system larg focus technolog
continu grow increas demand tool
new product launch high-throughput categori
introduc novaseq price
custom continu adopt platform
multi-year period instrument set alreadi
help reduc cost sequenc genom
previou standard expect
technolog enabl genom eventu
continu improv reagent technolog
continu improv upon nextseq platform price
enjoy european approv
mid-throughput categori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
clinic research vitro-diagnost test along
flexibl output option mid- high-throughput
platform instal base continu grow fast pace
posit pull-through consum recent
risen compani previou target system
becom increasingli valuabl lab variou
applic low-throughput categori could
help smaller clinic diagnost lab extend
capabl sequenc current offer three
instrument iseq offer compact
sequenc solut low price
target gene small genom sequenc lab
increasingli use new instal system switch
cost associ workflow consist
reproduc concern continu rise along
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
market expand sequenc indic creat
larg growth opportun product
leapfrog platform lead market share
loss profit declin
larg grow instal base
signific on-going sale high-margin consum
instrument
oearly-stag sequenc toolmak may seek sell
rather compet directli
genom behemoth help illumina
keep competit edg
oa signific portion growth requir
clinic adopt sequenc technolog
face challeng beyond competit relat
regul valid treatment guidelin
success depend manag abil
sustain innov astut capit alloc
guarante
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
given potenti disrupt technolog genom
end market end june held
billion cash invest owe billion
convert debt princip time ebitda
significantli cash invest debt
remain confid abil meet oblig
even pay pend billion pacif
bioscienc acquisit debt convert
equiti matur million convert
per share million convert
per share expect compani cash flow gener
remain robust rel debt well million
gener grow billion
base-cas scenario compani share repurchas
author appear rel small million
avail june excess cash may continu
build balanc sheet compani pay
give high uncertainti rate
early-stag genom
sequenc market combin potenti
disrupt entrant highli technic field disrupt
technolog new genom sequenc platform
greatest risk view
fisher pacif bioscienc ventur capit
continu fund third-gener technolog could
consider research develop shift toward
technolog could elimin need complic
sampl prepar camera laser beyond
potenti lower-cost faster simpler use
rapid pace
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
read length suggest easier align sequenc
less-compl data manag softwar
program awar multipl ventur develop
new sequenc technolog state advanc
difficult determin think technolog
earli phase develop suggest
near-term threat howev platform
nanopor shown promis earli publish
numer sequenc technolog fail
take flight includ method helico
point emerg technolog remain
larg untest
like face numer
develop challeng give
room run least intermedi term
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
american fund growth fund amer
capit research manag compani
share
fund
share
fund
assign exemplari stewardship rate
base compani histori shrewd capit alloc
help firm maintain return
doubl capit cost view innov
support high research develop
spend combin prescient well-tim
acquisit activ upheld impress
growth return
domin sequenc market larg stem
acquisit solexa gave
foundat
sequenc
machin persist leadership push
sequenc innov curv also build
sampl prepar data analysi posit
prefer sequenc platform
moleculo pacif bioscienc
pend
address platform weak
acquisit includ bluegnom verinata
help lay groundwork growth
manag face tall order quest sustain
blister pace
develop
field potenti disrupt
technolog one seriou misstep failur acquir
long-term success manag team
like cogniz threat anyon els
though think excel drive industri
innov pick winner capit deploy
jay flatley illumina ceo
transit role execut chairman like
continu consider input
strateg initi franci desouza succeed flatley
ceo juli join compani symantec
presid addit flatley execut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
chairman role desouza possess seat
board director john thompson -- board
member sinc former ceo symantec -- replac
blain bowman lead independ director follow
retir compens determin larg
revenu oper incom target perform
stock unit track earn per share benchmark
three-year period arent best measur valu
creation opinion that minor quibbl relat
compani histor perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
qiagen enjoy posit moat trend
genom appear fairli valu sep
take fresh look genom firm
maintain moat rate -- narrow
none -- increas moat
trend posit stabl on-going innov
help compani expand new market opportun
keep long-term growth higher pace
firm life science/diagnost coverag also
valuat perspect recent price drop push
share closer fair valu opinion
although significantli differ view qualiti
underli busi reflect moat
rate see posit moat trend compani
relat strong innov pipelin look like
open new market opportun organ
specif remain focus reduc cost
genom sequenc make technolog
access broader rang applic includ
clinic diagnost go forward addit grow
sequencing-rel busi also pursu new
platform expans diagnost platform
test pipelin long-term growth
margin trajectori firm look strong new product
launch also contribut expand intang
asset switch cost compani
howev near-term outlook
remain long-term prospect pullback
share recent month stock appear
reason valu opinion share recent
trade slight premium new fair valu
estim per share share trade roughli
line fair valu estim per share
experienc weaker growth due
varieti challeng expect growth acceler
beyond pressur subsid
support current fair valu estim first
microarray busi declin relat direct-to-
consum product face tough compar
sever strong year particularli market
servic like ancestri servic like
may need adjust strategi includ health-
relat offer could requir complex
sequenc expand geograph could
eventu benefit also compani see
weaker-than-anticip use consum non-
high-throughput machin may repres
anomali accord manag keep close
eye trend sinc competit forc may work
well
final sever popul genom project would
perform high-throughput instrument
ramp quickli expect view dynam
mere delay growth area rather
perman event includ weak near-term
trend expect mid-single-digit sale earn
per share growth expect
grow depress rate long given larg
opportun ahead compani last four
year explicit forecast period expect
return midteen sale high teen earn per share
expect earn time expect earn
see stock fairli valu howev growth look
like remain weak beyond would
surpris see pullback stock could
provid attract entri point
similarli long-term outlook stronger
near-term prospect specif expect mid-
single-digit growth top bottom line
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
includ breakdown chines
joint ventur provid sequenc servic full
innov pipelin though expect top-
bottom-lin growth acceler beyond sale
growth earn per share growth compound
annual basi expect appear
roughli line manag expect
constant-curr revenu growth least
earn per share growth period share
trade around time expect earn
time expect earn view share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
